Browsing by Author "Taheri, Yasaman"

Now showing 1 - 3 of 3

NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer’s Disease
(Bentham Science Publishers B.V., 2023-03) Painuli, Sakshi; Semwal, Prabhakar; Zam, Wissam; Taheri, Yasaman; Ezzat, Shahira M; Zuo, Peijun; Li, Liping; Kumar, Dileep; Sharifi-Rad, Javad; Cruz-Martins, Natália
Alzheimer’s disease (AD) is an increasingly common neurodegenerative disease that at- tracts the attention of researchers and medical community in order to develop new, safe and more effective drugs. Currently available drugs could only slow the AD progression and relieve the symptoms, in addition to being linked to moderate-to-severe side effects. N-methyl D-aspartate (NMDA) receptors antagonists were reported to have the ability to block the glutamate-mediated excitotoxic activity being good therapeutic targets for several neurodegenerative diseases, includ- ing AD. Based on data obtained so far, this review provides an overview over the use of NMDA antagonists for AD treatment, starting with a key emphasis on present features and future aspects regarding the use of NMDA antagonists for AD, and lastly a key focus is also given on its use in precision medicine.
NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer Disease
(Bentham Science Publishers, 2022-04) Painuli, Sakshi; Semwal, Prabhakar; Zam, Wissam; Taheri, Yasaman; Ezzat, Shahira M; Zuo, Peijun; Li, Liping; Kumar, Dileep; Sharifi-Rad, Javad; Cruz- Martins, Natália
Alzheimer disease (AD) is an increasingly common neurodegenerative disease, and therefore researchers and medical community are devoting a key attention in searching new, safer and more effective drugs than the currently available ones. Currently available drugs are not an effective treatment to the disease, they only slow the AD progression and act in symptoms relief, despite being linked to moderate-to-severe side effects. N-methyl D-aspartate (NMDA) receptors antagonists and cholinesterase inhibitors, and combination therapy, are the most often used therapeutic regimens in AD patients. In particular, NMDA receptors have being target of an increasing attention while good therapeutic targets for several neurodegenerative diseases, including AD, due to their ability to block the glutamate-mediated excitotoxic activity. Based on data obtained so far, this review provides an overview on the use of NMDA antagonists for AD treatment, starting with a key emphasis on present features and future aspects on the use of NMDA antagonists for AD, and lastly a key focus is also given on its use for precision medicine.
Urtica dioica-Derived Phytochemicals for Pharmacological and Therapeutic Applications
(Hindawi, 2022-02) Taheri, Yasaman; Quispe, KCristina; Herrera-Bravo, Jesu´s; Sharifi-Rad, Javad; Ezzat, Shahira M; Merghany, Rana M; Shaheen, Shabnum; Azmi, Lubna; Mishra, Abhay Prakash; Sener, Bilge; Kılıç, Mehtap; Sen, Surjit; Acharya, Krishnendu; Nasiri, Azadeh; Cruz-Martins, Nata´lia; Fokou, Patrick Valere Tsouh; Ydyrys, Alibek; Bassygarayev, Zhandos; Das¸an, Sevgi Durna; Alshehri, Mohammed M; Calina, Daniela; Cho, William C
Urtica dioica belongs to the Urticaceae family and is found in many countries around the world. 1is plant contains a broad range of phytochemicals, such as phenolic compounds, sterols, fatty acids, alkaloids, terpenoids, flavonoids, and lignans, that have been widely reported for their excellent pharmacological activities, including antiviral, antimicrobial, antihelmintic, anticancer, nephroprotective, hepatoprotective, cardioprotective, antiarthritis, antidiabetic, antiendometriosis, antioxidant, anti-inflammatory, and antiaging effects. In this regard, this review highlights fresh insight into the medicinal use, chemical composition, pharmacological properties, and safety profile of U. dioica to guide future works to thoroughly estimate their clinical value.